Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Active-Controlled Study of CB-183,315 vs Vancomycin in Clostridium difficile-associated Diarrhea
2012-000252-34Phase 3Completed
- Sponsor
- Cubist Pharmaceuticals, Inc.
- Start
- Sep 2012
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of surotomycin in Clostridioides difficile colitis (CDI) (2 arms), sponsored by Cubist Pharmaceuticals, Inc. Primary endpoint: Primary Efficacy Endpoint. Started Sep 2012; status: completed.
02
Drugs
surotomycin
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2012-000252-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000252-34.